3.4 Biotransformation and drug metabolism

Biotransformation and drug metabolism are the body's mechanisms for chemically altering drugs so they can be eliminated. These processes directly determine how long a drug stays active, how effective it is, and whether it causes toxicity. They also explain why two patients can take the same dose of the same drug and have very different responses.

This topic covers the organs responsible for drug metabolism (with a focus on the liver), the cytochrome P450 enzyme system that drives most Phase I reactions, and the genetic variations that make people metabolize drugs at different rates.

Drug metabolism: Purpose and process

Biochemical modification and elimination of drugs

Drug metabolism is the body's way of chemically modifying drugs so they become easier to excrete. Without metabolism, many lipophilic (fat-soluble) drugs would stay in the body far too long because they'd just get reabsorbed instead of being eliminated.

The process typically happens in two phases:

• Phase I reactions (functionalization) introduce or expose a functional group on the drug molecule. The three main reaction types are oxidation, reduction, and hydrolysis. Think of Phase I as "unmasking" a spot on the molecule where Phase II can attach something.
• Phase II reactions (conjugation) attach a large, water-soluble molecule to the drug or its Phase I metabolite. Common conjugation partners include glucuronic acid, sulfate, and amino acids.

The net result is increased water solubility, which allows the kidneys or bile to excrete the drug. Not every drug goes through both phases; some skip Phase I entirely, and some are already water-soluble enough after Phase I alone.

One important wrinkle: metabolism doesn't always inactivate a drug. Some metabolites are pharmacologically active and contribute to the drug's effects. In the case of prodrugs, the metabolite is actually the intended active form (codeine, for example, must be converted to morphine by CYP2D6 to produce its analgesic effect).

Impact on drug efficacy and toxicity

The rate and extent of metabolism shape several clinically important outcomes:

• Drug efficacy depends on whether enough active drug reaches its target. Rapid metabolism can reduce efficacy; slow metabolism can prolong or intensify effects.
• Toxicity can result from accumulation of the parent drug or from toxic metabolites (acetaminophen's metabolite NAPQI is a classic example).
• Duration of action is directly tied to how quickly the body clears the drug.
• First-pass metabolism reduces the bioavailability of many orally administered drugs. After absorption from the gut, blood flows through the liver via the portal vein before reaching systemic circulation. Drugs that undergo extensive first-pass metabolism (like nitroglycerin) may have very low oral bioavailability.
• Drug-drug interactions occur when one drug inhibits or induces the enzymes that metabolize another, raising or lowering the second drug's levels in unpredictable ways.
• Individual variation in metabolic enzyme activity (due to genetics, age, liver disease, etc.) means the same dose can produce very different plasma concentrations in different patients.

Organs involved in drug metabolism

Primary metabolic organs

The liver is by far the most important organ for drug metabolism. It contains the highest concentration of drug-metabolizing enzymes and performs the bulk of both Phase I and Phase II reactions. The liver's position in the portal circulation is what makes first-pass metabolism possible.

The gastrointestinal tract also plays a significant role, particularly the intestinal epithelium, which expresses CYP3A4 enzymes. For orally administered drugs, metabolism can begin before the drug even reaches the liver. The gut and liver together account for most first-pass metabolism.

The kidneys contribute through various enzymatic reactions and are especially relevant for drugs that are primarily excreted in urine. Some metabolic conversion occurs in renal tissue itself.

Secondary metabolic organs

• Lungs contain enzymes that metabolize some inhaled drugs (notably inhaled anesthetics) and airborne toxins
• Skin possesses metabolic enzymes that affect topically applied drugs and transdermal medications
• Brain has limited metabolic capacity but can metabolize certain neuroactive compounds, which matters for local drug concentrations of centrally-acting medications
• Other tissues (heart, skeletal muscle, blood) contribute to a lesser extent and are usually only clinically relevant for specific drugs

Cytochrome P450 enzymes in drug metabolism

Structure and function of CYP450 enzymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing proteins that play the central role in Phase I drug metabolism. They're located primarily in the endoplasmic reticulum of hepatocytes (liver cells).

These enzymes catalyze several types of oxidative reactions:

• Hydroxylation: adding an $-OH$ group to the drug molecule
• Dealkylation: removing an alkyl group
• Epoxidation: forming an epoxide ring

A key feature of CYP450 enzymes is their broad substrate specificity. A single isoform can metabolize many structurally different drugs, which is why drug-drug interactions through this system are so common.

The major CYP450 isoforms you need to know:

Regulation and variability of CYP450 activity

CYP450 enzyme activity isn't fixed. It can be increased (induced) or decreased (inhibited) by several factors:

• Other drugs: This is the most clinically important cause of drug-drug interactions. Rifampin, for example, is a potent inducer of CYP3A4, meaning it speeds up metabolism of other drugs processed by that enzyme. Ketoconazole is a potent CYP3A4 inhibitor, doing the opposite.
• Dietary components: Grapefruit juice inhibits intestinal CYP3A4, which can significantly increase blood levels of drugs like certain statins and calcium channel blockers.
• Environmental compounds: Cigarette smoke induces CYP1A2, which is why smokers may need higher doses of drugs metabolized by that enzyme.

Induction takes days to develop (the body needs to synthesize more enzyme protein), while inhibition can occur almost immediately.

Genetic polymorphisms add another layer of variability. Different people carry different versions of CYP450 genes, leading to differences in enzyme activity that are present from birth. Expression levels also vary between populations and tissues.

Genetic variations and drug metabolism

Types of genetic variations affecting drug metabolism

The most common genetic variations affecting drug metabolism are:

• Single nucleotide polymorphisms (SNPs) in CYP450 genes alter enzyme activity or expression. For example, the CYP2D6*4 allele produces a nonfunctional enzyme, and CYP2C19*2 results in a defective splice site that eliminates enzyme activity.
• Copy number variations (CNVs) change the number of functional gene copies a person carries. Someone with multiple copies of the CYP2D6 gene will produce more enzyme and metabolize CYP2D6 substrates faster than normal.
• Variations in non-CYP450 genes also matter. Phase II enzymes (like UGTs and GSTs) and drug transporters (like ABCB1 and SLCO1B1) have their own clinically relevant polymorphisms.

Impact of genetic variations on drug therapy

Based on their genetic makeup, individuals are classified into four metabolizer phenotypes:

• Poor metabolizers: greatly reduced or absent enzyme activity. At standard doses, drug levels may build up to toxic concentrations.
• Intermediate metabolizers: somewhat reduced activity. May need modest dose reductions for some drugs.
• Extensive (normal) metabolizers: typical enzyme activity. Standard dosing guidelines are designed for this group.
• Ultrarapid metabolizers: increased enzyme activity (often from gene duplication). Standard doses may be ineffective because the drug is cleared too quickly. For prodrugs, the opposite problem occurs: too much active metabolite is produced too fast.

Pharmacogenetic testing identifies these variations before treatment begins. A well-known example is warfarin dosing: testing for CYP2C9 and VKORC1 genotypes helps predict the dose a patient will need, reducing the risk of bleeding or clotting complications.

Ethnic and population differences in allele frequencies are clinically relevant. For instance, roughly 5-10% of Caucasians are CYP2D6 poor metabolizers, compared to about 1-2% of East Asian populations. Conversely, ultrarapid CYP2D6 metabolism is more common in certain North African and Middle Eastern populations.

These genetic differences are a major reason pharmacology is moving toward precision medicine, where drug selection and dosing are tailored to an individual's genetic profile rather than relying on one-size-fits-all approaches.